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Background: The aim of the present study was to assess whether the efficacy of bisphosphonate treatment is
influenced by PTH levels measured in newly diagnosed osteoporotic patients and to identify the threshold value,
beyond which PTH level negatively influences therapeutic efficacy.
Methods: One hundred and thirty-eight osteoporotic patients were enrolled into the study. All subjects underwent
laboratory screening, bone densitometry with DEXA, and x-ray imaging. The changes in bone density were
evaluated after a mean follow-up period of 13.37 ± 1.29 months. Correlation analysis was performed on the clinical
data of patients, the percentage changes of BMD values, and the PTH levels measured at the beginning of study,
using SPSS software.
Results: The mean age of the subjects was 64.82 ± 10.51 years, and the female-to-male ratio was 116/22.
Baseline BMD value measured with AP DEXA scanning was 0.854 ± 0.108 g/cm2 in the L1-4 vertebrae and
0.768 ± 0.115 g/cm2 in the left femoral neck. By the end of the follow-up period, these values changed to
0.890 ± 0.111 g/cm2 and 0.773 ± 0.111 g/cm2, respectively. We found a statistically significant, negative
correlation between PTH levels and the percentage changes of lumbar BMD values measured at the end of
the follow-up (correlation coefficient R2 = 0.121, p < 0.0001). The analysis of frequency histograms suggested
that negative effects on bone might be expected above a PTH level of 60 pg/mL (7.3 pmol/L).
Conclusion: Our findings imply that a baseline PTH level over 60 ng/mL can reduce the efficacy of
bisphosphonate treatment.
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Osteoporosis is considered a public health problem in
an increasing number of countries. According to the ini-
tial results of the epidemiological studies conducted in
Hungary during the mid-90’s, primarily in international
co-operation, the nationwide prevalence of osteoporosis
in the population over 50 years of age was 32.3% among
women and 23.6% among men [1]. This means that
osteoporosis afflicts approximately 600,000 women and
more than 300,000 men overall in Hungary [2].
Anti-resorptive agents, including oral or parenteral
aminobisphosphonates (e.g. alendronate, risedronate,
ibandronate, and zolendronate), with a mechanism of ac-
tion based on the blockade of mevalonate metabolism,* Correspondence: gaalja@freemail.hu
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reproduction in any medium, provided the orplay an outstanding role in the management of osteopor-
osis. These agents inhibit the isoprenylation of small
GTPases, which are signalling proteins important in the
maintenance of cell structure [3].
Calcium and vitamin D sufficiency is a prerequisite to
effective antiresorptive therapy, especially in the elderly
population [4]. Low vitamin D3 level triggers the com-
pensatory release of parathormone (PTH) [5], which
increases the risk of fractures [6], as well as interference
with neuromuscular function [7,8]. Vitamin D suffi-
ciency, as well as optimal levels of activated vitamin D3
(1,25-dihydroxy-vitamin D) can suppress PTH secretion
[9]. Above-normal PTH levels were detected in 17.4% of
postmenopausal women treated for osteoporosis [10],
and a negative correlation was found between PTH and
vitamin D levels [11]. When 25(OH)-vitamin D levelLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The baseline characteristics of the sudy
population
Number of patients 138
Women/men 116/22
Mean age (years) 64.82 ± 10.51
Treatment Alendronate:97
Risedronate: 19
Zolendronate: 7
Ibandronate:15
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the upper limit of the normal range (65 pg/mL) [12].
There were some important premises that have
prompted us to conduct this study. According to the
Bhattoa et al., serum 25(OH)-vitamin D3 is below nor-
mal in 56.7% of postmenopausal women in Hungary
[13], and a significant portion of these patients expectedly
have higher than normal PTH levels. Unfortunately,
bone loss continues despite adequate bisphosphonate
therapy and supplementation with calcium and vitamin
D3 in 8 to 23% of osteoporotic patients (bisphosphonate
resistance) [14], and several publications have suggested
a role for secondary hyperparathyroidism in the aetiology
of bisphosphonate resistance [15,16].
The aim of the present study was to assess the preva-
lence of secondary hyperparathyroidism (vitamin D3 defi-
ciency) among newly diagnosed osteoporotic patients and
to evaluate whether baseline levels of PTH influence the
efficacy of anti-osteoporotic treatment (with bisphospho-
nates) in this population. Furthermore, we determined the
threshold, beyond which PTH level has a negative impact
on the efficacy of bisphosphonate treatment.
Methods
Type of study
This study was a prospective, observational, non-
interventional study.
Inclusion and exclusion criteria
Patients meeting the following criteria were eligible
for inclusion: i) diagnosed idiopathic osteoporosis with
a lumbar and/or femoral T-score lower than −2.5;
ii) patients newly identified and enrolled to follow-up;
iii) patients with laboratory findings available.
The exclusion criteria were as follows: i) diagnosed
secondary osteoporosis; ii) history of a malignancy;
iii) renal failure (GFR <65 mL/min according to the
Cockroft-Gault formula); iv) severe liver disease; v)
hypo-/hyperthyroidism; vi) malabsorption syndrome;
vii) hypercalcaemia; viii) hypocalcaemia; ix) history of
renal calculosis; x) previous anti-osteoporotic therapy
with bisphosphonates, selective estrogen-receptor
modulators (SERMs), strontium ranelate, teriparatide,
or calcitonin.
Study population
Two hundred and thirty-two patients met the inclusion
criteria, and data from 138 (116 women and 22 men,
with a mean age of 64.82 ± 10.51 years and between 43
and 81 years) were available at the time of the ebd of the
study. Written informed consent for participation was
obtained from each patient. Ninety-seven patients
received alendronate, 19 risedronate, 7 zolendronate,
and 15 ibandronate. At baseline, 13 patients had aprevalent vertebral, and 59 a prevalent non-vertebral
fracture, while 22 had multiple fractures (Table 1.)
The study protocol was approved by the Regional Re-
search Ethics Committee of the Univeristy of Debrecen,
Medical and Health Science Center.
Study endpoints
The primary endpoint of the study was the change of
bone mineral density (BMD) values (and T-scores) dur-
ing one year with appropriate combination therapy with
a bisphosphonate, vitamin D3, and calcium.
Implementation of the study
At baseline, the patient’s medical history was taken, and
physical examination was performed. All subjects under-
went bone densitometry of the lumbar spine (L1-4 verte-
brae) and of the left femoral neck with antero-posterior
dual-energy x-ray absorptiometry (AP DEXA) scanning,
as well as an x-ray of the dorsal-lumbar spine. Labora-
tory screening comprised the following: erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), complete
blood count (CBC), serum calcium and phosphate, blood
urea nitrogen (BUN), creatinine, aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), alkaline phos-
phatase, serum albumin, urinary calcium/creatinine ratio,
thyroid stimulating hormone (TSH), intact parathyroid
hormone (iPTH), osteocalcin, carboxy-terminal collagen
crosslinks (CTX).
Serum PTH was measured using electrochemilumi-
nescence immunoassay (Roche Diagnostics GmbH,
Mannheim, Germany), where the inter-assay CV was
<7%. This assay employs a sandwich test principle in
which a biotinylated monoclonal antibody reacts with
the N-terminal fragment (1–37), and a monoclonal
antibody labeled with a ruthinium complex reacts
with the C-terminal fragment (38–84). The antibodies
in this assay are reactive with epitopes in the amino
acid regions 26–32 and 37–42.
We repeated the DEXA scan after a one-year
(13.37 ± 1.29 months) follow-up on the average, and
recorded the number of incident bone fractures and
cases of renal stone formation that had occurred du-
ring this period.
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apy with alendronate, risedronate, or ibandronate admi-
nistered in combination with 6000 IU/week vitamin D3,
as well as 1000 mg/day calcium during the follow-up
period.
The patients’ compliance was evaluated at the sched-
uled quarterly visit, and a more than 80% compliance
was acceptable to continue the study.
Statistical analysis
We formed two subgroups based on the change in bone
mineral density (BMD) values as a result of therapy. The
group of responders included all those patients in whom
BMD level decreased as compared to the baseline value;
the rest of the patients formed the group of non-
responders. The definition of bone loss (non-responders)
was made if the bone mineral density was decreased by
more than 1% of the initial value, because the variation co-
efficient is less than 1% in the case of Lunar Prodigy DXA
device, which was used in this study. The normality of the
distribution of datasets was checked with Kolmogorov-
Smirnov test. We compared data from two independent
groups using Mann–Whitney test. A general linear model
was used to identify the factors influencing the magnitude
of the change in bone density of the spine and of the
femoral neck. All statistical analyses were performed with
version 19.0 of the IBM SPSS Statistics software package.Figure 1 Baseline parathormone levels in the responder and non-resp
responders/, 1: improving bone mineral density/responders/).Results
On enrolment in the study, PTH levels were normal in
112 patients, while it elevated in 26 cases. Baseline BMD
measured at the L1-4 vertebrae, and at the left femoral
neck by AP DEXA scanning was 0.854 ± 0.108 g/cm2,
and 0.768 ± 0.115 g/cm2, respectively.
After a follow-up period and appropriate therapy for
over one year on average, bone density increased to
0.890 ± 0.111 g/cm2 at the lumbar spine, and to 0.773 ±
0.111 g/cm2 at the femoral neck. Thus, the mean increase
in BMD was 0.036 g/cm2 and 0.005 g/cm2, respectively.
We found a statistically significant (p < 0.0001) differ-
ence between the baseline PTH levels of patient subsets
with declining or non-declining bone density (using ei-
ther BMD or T-score as the basis for grouping). How-
ever, creating these subsets according to femoral bone
density (based on either the BMD or the T-score), the
difference between PTH values was no longer significant
(Figure 1).
The general linear model showed a strong, significant
(p < 0.0001) relationship between baseline PTH levels
and the relative change in lumbar BMD (Figure 2). A
similar correlation could not be demonstrated for the
femoral neck, other variables (such as age, gender, etc.),
and the change in BMD (p > 0.05).
We determined the prognostically optimal threshold
of baseline PTH level, which best differentiated theonder subsets (0: declining bone mineral density/non-
Figure 2 The relationship between baseline parathormone levels, and the changes in lumbar bone mineral density.
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each other. According to the frequency histogram (of
PTH level plotted in units of 5 pg/mL), this was at ap-
proximately 60 pg/mL for the lumbar spine (Figure 3).
Regarding the femoral neck, the frequency histogram
did not show any substantial difference between the sub-
sets with improving or declining bone density.
New (incident) vertebral or non-vertebral fractures oc-
curred in one and five subjects, respectively.
Discussion
Vitamin D3 deficiency and accompanying secondary
hyperparathyroidism are extremely prevalent in theFigure 3 The frequency histogram of the parathormone levels in respsenior population of developed countries – regardless of
geographical location or terrestrial latitude [17]. The
weight of this problem is illustrated – among others –
by a survey conducted in Austria, the United Kingdom
(UK), and Mexico. This study revealed that the propor-
tion of patients receiving calcium and vitamin D3 sup-
plementation was 73% in Austria, 15% in the UK, and
12% in Mexico. Furthermore, only 20% of the patients in
Austria were taking vitamin D3 – where the latter was
provided free to osteoporotic patients [18,19].
In 98% of patients hospitalized for non-traumatic frac-
tures, 25(OH) vitamin D3 levels were found to be low,
which was commonly associated with elevated PTH levelonders and non-responders.
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lationship has been shown between the risk of osteopor-
otic hip fractures and increased vitamin D3 intake, as
well as greater adherence to supplementation [22].
There is an increasing number of reports suggesting
that inadequate (<30 ng/mL) serum 25(OH) vitamin D3,
and consecutively elevated PTH levels are among the es-
sential factors behind bisphosphonate resistance, leading
to unsatisfactory response to bisphosphonates [15,16].
Previous studies have demonstrated that the increase
of BMD in every skeletal region is greater in vitamin D-
replete patients than in those with vitamin D deficiency.
Additionally, the risk of incident osteoporotic fractures
is 1.77 times higher in the latter population, than in vita-
min D-replete individuals [23].
Our findings confirm that elevated (>60 pg/mL) serum
PTH levels exert an unfavourable influence on the efficacy
of bisphosphonate therapy. We believe it would be import-
ant to determine PTH levels before bisphosphonate treat-
ment is initiated. In particular, similar to a variety of other
disorders, such as diabetes and hypertension, the success of
anti-osteoporotic therapy is essentially dependent on a spe-
cific target PTH level (<60 pg/mL in uor case). From an
economic point of view, the cost of a single PTH measure-
ment is far less than the annual expenditure on ineffective
bisphosphonate therapy.
It is controversial whether administering an initial, oral
loading dose of (40000 to 300000 IU) vitamin D is justified
before initiating anti-resorptive therapy in hypovitaminosis
D3. The administration of a single, 300000-IU dose of vita-
min D3 could successfully normalize the serum 25(OH)
vitamin D3 levels of patients within three months, without
major adverse effects [24]. Regarding the 30 ng/mL
(75 nmol/L) serum 25(OH) vitamin D3 concentration as
the target level, others have provided therapeutic recom-
mendations on the single loading dose [25].
The fracture-reducing effect of daily supplementation
with 800 to 1000 IU oral vitamin D3 is evident. In direct
contrast to this, others have observed an increase (com-
pared to placebo) in the number of falls, and fractures
among their elderly female patients treated with yearly
oral mega-dose (500000 IU) of vitamin D3 [26].
Although the authors could not explain this finding,
the need for reducing the excessively high baseline level
of PTH has not been fully addressed in previous studies.
Serum PTH levels, the vitamin D3-replete state, and
supplementation with vitamin D3 are of significant im-
portance in osteology. It is highly probable that the higher
(>60 pg/mL in our study) baseline PTH levels observed
before the initiation of anti-osteoporotic treatment have a
clear effect on the therapy outcome. Whether long-term
oral vitamin D supplementation or the administration of a
single high dose vitamin D3 treatment is justified can be
determined by additional large-scale studies.Conclusion
This is the first study indicating the connection between
the treatment efficacy and the PTH levels in newly diag-
nosed osteoporotic patients. Moreover, we determined a
potentially “harmful” cut-off value for PTH levels. Our
results suggest that the PTH levels higher than 60 pg/mL
have negative prognostic value for the efficacy of antiporotic
treatment.
Study limitations and strength
The relatively low patient number and the short follow-up
are the possible limitations of this study. The main
strenght of the study is that this is the first study to deter-
mine a cut-off PTH value, which affect the success of the
bisphosphonate treatment in patients with osteoporosis.
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